Browse

One of the most powerful pharmaceutical lobbying groups is launching a new seven-figure advertising blitz targeting a federal drug discount program

The cruise ship hantavirus outbreak, 988 staffing problems, and more health news from Morning Rounds

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.